Amgen (AMGN) director receives 665 RSUs in immediate stock grant

Rhea-AI Filing Summary

Amgen Inc. director Robert Eckert received an equity award of 665 shares of common stock on May 19, 2026, reported as a grant or other acquisition at no purchase price. The award came from vested Restricted Stock Units under Amgen’s 2009 director incentive programs and vested immediately.

After this grant, Eckert directly holds 26,251 shares of Amgen common stock. This total includes 3,943 dividend equivalents (DEs) credited to his unvested RSUs under a dividend reinvestment plan, which will pay out in shares as those RSUs vest.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ECKERT ROBERT

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	665	$0.00	--

Holdings After Transaction: Common Stock — 26,251 shares (Direct, null)

Footnotes (1)

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule. These shares include 3,943 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Key Figures

RSU shares granted: 665 shares Post-transaction holdings: 26,251 shares Dividend equivalents: 3,943 DEs +1 more

4 metrics

RSU shares granted 665 shares Vested RSUs paid in common stock on May 19, 2026

Post-transaction holdings 26,251 shares Total Amgen common shares held directly after grant

Dividend equivalents 3,943 DEs DEs tied to unvested RSUs under dividend reinvestment plan

Grant price $0.00 per share Equity award, not an open-market purchase

Key Terms

Restricted Stock Units (RSUs), Dividend Equivalents (DEs), dividend reinvestment plan, deferral schedule

4 terms

Restricted Stock Units (RSUs) financial

"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Dividend Equivalents (DEs) financial

"These shares include 3,943 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"

dividend reinvestment plan financial

"subject to a qualifying dividend reinvestment plan"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

deferral schedule financial

"Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ECKERT ROBERT

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320-1799

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		A		665	A	$0	26,251(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

2. These shares include 3,943 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Robert A. Eckert	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Amgen (AMGN) director Robert Eckert report?

Robert Eckert reported receiving 665 Amgen shares via a grant of vested Restricted Stock Units. The RSUs were awarded under Amgen’s 2009 director incentive programs and converted into common stock immediately, representing compensation rather than an open-market stock purchase or sale.

How many Amgen shares does Robert Eckert hold after this Form 4 filing?

After the reported grant, Robert Eckert directly holds 26,251 Amgen common shares. This total includes 3,943 dividend equivalents related to unvested RSUs, which will be paid in additional shares on a one-to-one basis when the corresponding restricted stock units vest in the future.

Was Robert Eckert’s Amgen Form 4 transaction a stock purchase or sale?

The Form 4 shows a grant or award acquisition, not an open-market trade. Eckert received 665 shares at a price of $0.00 per share through vested RSUs, reflecting equity compensation rather than buying shares on the market or selling existing holdings for cash.

What are the Amgen Restricted Stock Units (RSUs) mentioned in Robert Eckert’s filing?

The RSUs are stock-based awards granted under Amgen’s 2009 Director Incentive Program and equity plan. They convert into Amgen common shares on a one-to-one basis when vested. In this case, the RSUs vested immediately and were paid in shares of common stock to the director.

What are the 3,943 DEs referenced in Robert Eckert’s Amgen holdings?

The 3,943 DEs are dividend equivalents granted under Amgen’s equity incentive plan and tied to unvested RSUs. They accrue through a qualifying dividend reinvestment plan and are paid out in Amgen common shares, plus cash for any fractional amount, following the RSUs’ vesting schedule.